Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot(Centre Hospitalier Régional et Universitaire de Nancy), Valérie Lauwers‐Cancès(Université Fédérale de Toulouse Midi-Pyrénées), Jill Corre(Université Toulouse III - Paul Sabatier), Nelly Robillard(Centre Hospitalier Universitaire de Nantes), Cyrille Hulin(Université de Bordeaux), Marie‐Lorraine Chrétien(Maison des Sciences sociales et des Humanités de Dijon), Thomas Dejoie(Laboratoire de Biologie Structurale de la Cellule), Sabrina Mahéo(Université Toulouse III - Paul Sabatier), Anne-Marie Stoppa(Institut Paoli-Calmettes), Brigitte Pegourié(Université Grenoble Alpes), Lionel Karlin(Université de Lyon), Laurent Garderet(Sorbonne Université), Bertrand Arnulf(Hôpital Saint-Louis), Chantal Doyen(UCLouvain), Nathalie Meuleman(Institut Jules Bordet), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Jean‐Richard Eveillard(Centre Hospitalier Régional Universitaire de Brest), Lotfi Benboubker(Université de Tours), Mamoun Dib(Université d'Angers), Olivier Decaux(Université de Rennes), Arnaud Jaccard(Université de Limoges), Karim Belhadj(Université Paris-Est Créteil), Sabine Bréchignac(Université Sorbonne Paris Nord), Brigitte Kolb(Centre Hospitalier Universitaire de Reims), Cécile Fohrer(Université de Strasbourg), Mohamad Mohty(Sorbonne Université), Margaret Macro(Université de Caen Normandie), Paul G. Richardson(Dana-Farber Cancer Institute), Victoria Carlton(Adaptive Biotechnologies (United States)), Martin Moorhead(Adaptive Biotechnologies (United States)), Tom Willis(Adaptive Biotechnologies (United States)), Malek Faham(Adaptive Biotechnologies (United States)), Kenneth C. Anderson(Dana-Farber Cancer Institute), Jean‐Luc Harousseau(Hôpital privé du Confluent), Xavier Leleu(Université de Poitiers), Thierry Façon(Lille’s Cardiology Hospital), Philippe Moreau(Centre Hospitalier Universitaire de Nantes), Michel Attal, Hervé Avet‐Loiseau(Université Toulouse III - Paul Sabatier), Nikhil C. Munshi(Dana-Farber Cancer Institute)
Cited by 417Open Access
Abstract
= .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.
Related Papers
International Staging System for Multiple Myeloma
Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al.|Journal of Clinical Oncology|2005|2.9k
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos et al.|New England Journal of Medicine|2014|1.3k